Morocco has introduced price reductions for hundreds of medicines, including treatments for chronic diseases, cardiovascular conditions and cancer, under a new ministerial order published in the country’s Official Gazette.
The order, issued by Health and Social Protection Ministerial Decision No. 2157.26 on Sept. 22, 2026, amends a 2014 decision governing the retail prices of original medicines, generics and biosimilars marketed in Morocco.
The measure is based on the country’s Medicines and Pharmacy Code, Law No. 17.04, and the law establishing the Moroccan Agency for Medicines and Health Products, Law No. 10.22. It follows consultations with the interministerial committee responsible for medicine prices and regulatory frameworks, on a proposal from the Moroccan Agency for Medicines and Health Products.
The revised price lists cover medicines used to treat a wide range of conditions, with reductions affecting both commonly prescribed drugs and specialized treatments that can impose significant financial burdens on patients and health insurance systems.
Among the medicines affected are cholesterol-lowering drug CRESTOR 10 mg, whose retail price for a box of 30 tablets fell from 167 dirhams to 99.50 dirhams, and NO LIP 10 mg, also sold in boxes of 30 tablets, which dropped from 154.10 dirhams to 99.50 dirhams.
The reductions also extend to costly cancer treatments. The retail price of IBRANCE 100 mg, a targeted therapy sold in boxes of 21 capsules, fell from 24,024 dirhams to 17,066 dirhams. Its net hospital price declined from 23,561 dirhams to 16,739 dirhams.
The price of ALECENSA 150 mg, used to treat certain advanced cancers and sold in boxes of 224 capsules, dropped from 44,479 dirhams to 32,863 dirhams — a reduction of 11,616 dirhams.
Other medicines affected include ENBREL 50 mg, supplied as prefilled injections, whose retail price fell from 6,315 dirhams to 5,005 dirhams.
Prices were also reduced for anticoagulants and blood disorder treatments. ELIQUIS 2.5 mg fell from 188.50 dirhams to 156.50 dirhams, while REFACTO AF 2,000 IU, used to treat hemophilia, dropped from 12,355 dirhams to 7,509 dirhams.
The government says its national medicines policy seeks to improve affordability, support the sustainability of social protection and compulsory health insurance funds, and reduce overall treatment costs for institutions covering patients’ medical expenses.
The policy also aims to encourage the use of generic medicines and maintain a regular, balanced supply of pharmaceutical products in the domestic market.
add your comment
Terms of publication : Not to offend the writer, people, sacred things, or attack religions or the divine self, and refrain from racist incitement and insults.